Extracellular matrix turnover and disease severity in Anderson-Fabry disease

Journal of Inherited Metabolic Disease

Volumn 30, Issue 1, 2007, Pages 88-95

  Shah, J S ^a   Hughes, D A ^a   Tayebjee, M H ^c   MacFadyen, R J ^c   Mehta, A B ^b   Elliott, P M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; ENZYME REPLACEMENT; EXTRACELLULAR MATRIX; FABRY DISEASE; FEMALE; HEART DISEASE; HEART VENTRICLE REMODELING; HUMAN; MALE; PATHOPHYSIOLOGY; SCORING SYSTEM; STEP WISE MULTIPLE REGRESSION; TURNOVER TIME;

ADULT; COHORT STUDIES; ENDOCARDIUM; EXTRACELLULAR MATRIX; FABRY DISEASE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MUTATION; REGRESSION ANALYSIS; SEX FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 33846440090     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-006-0360-6     Document Type: Article

References (35)

1. Altieri P, Brunelli C, Garibaldi S, et al (2003) Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 33 (8): 648-656.
2. Boutouyrie P, Laurent S, Laloux B, Lidove O, Grunfeld JP, Germain DP (2002) Arterial remodelling in Fabry disease. Acta Paediatr Suppl 91 (439): 62-66.
3. Desnick RJ, Ioannou YA, Eng CM (2001) αGalactosidase A deficiency: Fabry disease.In: Scriver CR, Beaudet al, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3733-3774.
4. Devereux RB, Reichek N (1977) Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55 (4): 613-618.
5. Devereux RB, Alonso DR, Lutas EM, et al (1986) Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 57 (6): 450-458.
6. Devereux RB, de Simone G, Pickering TG, Schwartz JE, Roman MJ (1998) Relation of left ventricular midwall function to cardiovascular risk factors and arterial structure and function. Hypertension 31 (4): 929-936.
7. Dolgilevich SM, Siri FM, Atlas SA, Eng C (2001) Changes in collagenase and collagen gene expression after induction of aortocaval fistula in rats. Am J Physiol Heart Circ Physiol 281 (1): H207-214.
8. Elleder M, Bradova V, Smid F, et al (1990) Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Archiv A Pathol Anat Histopathol 417 (5): 449-455.
9. Ferrans VJ, Hibbs RG, Burda CD (1969) The heart in Fabry's disease. A histochemical and electron microscopic study. Am J Cardiol 24 (1): 95-110.
10. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K (2001) Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141 (2): 211-217.
11. Kaden JJ, Dempfle CE, Sueselbeck T, et al (2003) Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction. Cardiology 99 (3): 140-144.
12. Kampmann C, Baehner F, Whybra C, et al (2002) Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40 (9): 1668-1674.
13. Lindsay MM, Maxwell P, Dunn FG (2002) TIMP-1: A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40 (2): 136-141.
14. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38 (11): 750-760.
15. McCawley LJ, Matrisian LM (2001) Matrix metalloproteinases: They're not just for matrix anymore! Curr Opin Cell Biol 13 (5): 534-540.
16. McDonnell S, Morgan M, Lynch C (1999) Role of matrix metalloproteinases in normal and disease processes. Biochem Soc Trans 27 (4): 734-740.
17. Mehta A, Ricci R, Widmer U, et al (2004) Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34 (3): 236-242.
18. Mills K, Vellodi A, Morris P, et al (2004) Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease. Eur J Pediatr 163 (10): 595-603.
19. Moon JC, Sachdev B, Elkington AG, et al (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24 (23): 2151-2155.
20. Nagao Y, Nakashima H, Fukuhara Y, et al (1991) Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A. Clin Genet 39 (3): 233-237.
21. Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274 (31): 21491-21494.
22. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 18 (5): 1135-1149.
23. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR (2002) Cardiac remodelling in end stage heart failure: Upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 88 (5): 525-530.
24. Shah JS, Hughes DA, Sachdev B, et al (2005a) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96 (6): 842-846.
25. Shah JS, Lee P, Hughes D, et al (2005b) The natural history of left ventricular systolic function in Anderson-Fabry disease. Heart 91 (4): 533-534.
26. Shimizu G, Hirota Y, Kita Y, Kawamura K, Saito T, Gaasch WH (1991) Left ventricular midwall mechanics in systemic arterial hypertension. Myocardial function is depressed in pressure-overload hypertrophy. Circulation 83 (5): 1676-1684.
27. Stetler-Stevenson WG, Seo DW (2005) TIMP-2: An endogenous inhibitor of angiogenesis. Trends Mol Med 11 (3): 97-103.
28. Sundstrom J, Evans JC, Benjamin EJ, et al (2004) Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: The Framingham Heart Study. Circulation 109 (23): 2850-2856.
29. Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY (2004a) Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 17 (9): 764-769.
30. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY (2004b) Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension: Relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens 17 (9): 770-774.
31. Tayebjee MH, Lip GY, MacFadyen RJ (2005a) Matrix metalloproteinases in coronary artery disease: Clinical and therapeutic implications and pathological significance. Curr Med Chem 12: 763-771.
32. Tayebjee MH, Tan KT, MacFadyen RJ, Lip GYH (2005b) Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: Relationship to disease severity. J Intern Med 257 (1): 110-116.
33. The Criteria Committee of the New York Heart Association (1994) Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Boston: Little, Brown, 253-256.
34. Weidemann F, Breunig F, Beer M, et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26 (12): 1221-1227.
35. Whybra C, Kampmann C, Krummenauer F, et al (2004) The Mainz Severity Score Index: A new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65 (4): 299-307.